By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Tonix Pharmaceuticals, Inc. 

509 Madison Ave.
Suite 306
New York  New York  10022  U.S.A.
Phone: 212-980-9155 Fax: 212-923-5700




Company News
Tonix Pharma (TNXP) Announces Conditional Acceptance Of Tonmya As Proposed Brand Name For TNX-102 SL (Cyclobenzaprine HCL Sublingual Tablets) For The Treatment Of PTSD 7/6/2017 11:27:46 AM
Tonix Pharma (TNXP) Participated In The "Pathophysiology Of Posttraumatic Stress Disorder: Rethinking Drug Targets” Summit Sponsored By U.S. Department Of Defense 6/15/2017 11:04:39 AM
Tonix Pharma (TNXP) To Present An Update Of FDA Designated Breakthrough Therapy-TNX-102 SL For PTSD At The 2017 Marcum Microcap Conference 6/12/2017 12:05:02 PM
Tonix Pharma (TNXP) Presented Retrospective Analyses Of Treatment Response And Remission To TNX-102 SL In A Phase II Military-Related PTSD Study 5/31/2017 11:00:30 AM
Tonix Pharma (TNXP) To Present Additional Clinical Results Of Military-Related PTSD Study At The 2017 American Society Of Clinical Psychopharmacology Annual Meeting 5/24/2017 11:06:31 AM
Tonix Pharma (TNXP) Presented Analyses Of Potential Moderators Of Treatment Response To U.S. FDA-Designated Breakthrough Therapy For PTSD, TNX-102 SL, In Phase II AtEase Study In Military-Related PTSD 5/23/2017 8:42:15 AM
Tonix Pharma (TNXP) Reports First Quarter 2017 Financial Results And Provides Programs Update 5/15/2017 8:55:11 AM
Tonix Pharma (TNXP) Announces Issuance Of U.S. Patent For Tnx-102 Sl Composition And Formulation: Designed For Transmucosal Absorption And Bedtime Daily Use 5/2/2017 8:10:58 AM
Tonix Pharma (TNXP) Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Programs Update 4/17/2017 7:55:34 AM
Tonix Pharma (TNXP) Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option 4/14/2017 7:46:38 AM